Sign inJoin waitlistJoin the waitlist

Reid Merryman

Director, Clinical Research, Division of Lymphoma · Mass General Brigham

Credentials: · · · · ·

History

Clinical Research · Mass General Brigham
Present
Mass General Brigham
Present

Hematology and Medical Oncology
Dana-Farber Cancer Institute
2016–2019
Internal Medicine
Brigham and Women's Hospital
2013–2016
Harvard Medical School
2009–2013
University of Notre Dame
2005–2009

Research

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
Blood · 2017 · First of 31 authors · 210 citations
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
Blood · 2017 · 206 citations
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation
Journal of Clinical Oncology · 2017 · 158 citations

Philippe Armand
38 papers
Ann LaCasce
26 papers
AH
Alex Herrera
24 papers
Caron Jacobsen
24 papers
Jennifer Crombie
21 papers · 1 as a fellow
David Fisher
19 papers
Austin Kim
17 papers
Eric Jacobsen
16 papers
Oreofe Odejide
13 papers
Matthew Davids
12 papers
Jennifer Brown
11 papers
Yago Nieto
10 papers

Clinical trials

Epco, Zanu, Ritux for R/R FL or MZL
Principal investigator · Recruiting · Phase 2
Reid Merryman, MD
2025–2030
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Principal investigator · Active not recruiting · Phase 2
Reid Merryman, MD
2023–2029
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Principal investigator · Recruiting · Phase 2
Reid Merryman, MD
2023–2030
Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma
Principal investigator · Active not recruiting · Phase 1
Dana-Farber Cancer Institute
2022–2033